In recent years, liver disease has become established as a significant predictor of poor perioperative outcomes [1]. Despite declining rates of hepatitis B and hepatitis C-related morbidity and mortality, there has been an increase in the prevalence and incidence of both alcoholic liver disease and metabolic associated fatty liver disease. The global prevalence of metabolic associated liver disease is approximately 35% and is forecasted to be the leading cause of liver transplantation within the next decade [2].
